|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400085891 |
|
最近更新日期: Date of Last Refreshed on: |
2024-06-20 11:30:15 |
|
注册时间: Date of Registration: |
2024-06-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国带状疱疹疾病负担与经济学评价研究 |
|
Public title: |
Disease burden and economic evaluation of herpes zoster in China |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国带状疱疹疾病负担与经济负担研究 |
|
Scientific title: |
Disease burden and economic burden of herpes zoster in China |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
夏祎祺 |
研究负责人: |
何平 |
|
Applicant: |
Yiqi Xia |
Study leader: |
Ping He |
|
申请注册联系人电话: Applicant telephone: |
+86 137 2033 7686 |
研究负责人电话: Study leader's telephone: |
+86 139 1116 0537 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2211110248@stu.pku.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
2211110248@stu.pku.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区学院路38号北京大学中国卫生发展研究中心 |
研究负责人通讯地址: |
北京市海淀区学院路38号北京大学中国卫生发展研究中心 |
|
Applicant address: |
China Center for Health Development Studies, Peking University, 38 Xue Yuan Road, Haidian District, Beijing 100191, China |
Study leader's address: |
China Center for Health Development Studies, Peking University, 38 Xue Yuan Road, Haidian District, Beijing 100191, China |
|
申请注册联系人邮政编码: Applicant postcode: |
100191 |
研究负责人邮政编码: Study leader's postcode: |
100191 |
|
申请人所在单位: |
北京大学中国卫生发展研究中心 |
||
|
Applicant's institution: |
China Center for Health Development Studies, Peking University |
||
|
研究负责人所在单位: |
北京大学中国卫生发展研究中心 |
||
|
Affiliation of the Leader: |
China Center for Health Development Studies, Peking University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
IRB00001052-24022 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京大学生物医学伦理委员会 |
||
|
Name of the ethic committee: |
PKU IRB |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-04-20 00:00:00 |
||
|
伦理委员会联系人: |
李洁 |
||
|
Contact Name of the ethic committee: |
Jie Li |
||
|
伦理委员会联系地址: |
北京大学医学部逸夫教学楼501室(海淀区学院路38号) |
||
|
Contact Address of the ethic committee: |
Room 501, Yifu Building, Peking University Health Science Center (38 Xueyuan Road, Haidian District) |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8280 5751 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京大学中国卫生发展研究中心 |
||||||||||||||||||||||
|
Primary sponsor: |
China Center for Health Development Studies, Peking University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区学院路38号北京大学中国卫生发展研究中心 |
||||||||||||||||||||||
|
Primary sponsor's address: |
China Center for Health Development Studies, Peking University, 38 Xue Yuan Road, Haidian District, Beijing 100191, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
长春百克生物科技股份公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Changchun Bcht Biotechnology Co. |
||||||||||||||||||||||
|
Target disease: |
herpes zoster |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
流行病学研究 |
||||||||||||||||||||||
|
Study type: |
Epidemilogical research |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
本研究的总体目标是了解带状疱疹在中国的流行状况、疾病负担及其对个人和社会经济的影响。具体目标包括:第一,描述和分析中国带状疱疹的流行病学特征,包括并发症和危险因素的情况。第二,评估带状疱疹及其并发症对患者生活质量的影响,包括疼痛、抑郁、睡眠质量等方面,以提高公众对疾病影响的认识和关注。第三,量化带状疱疹对医疗系统和社会经济的负担,涉及医疗费用、生产力损失、家庭照顾成本等方面,为决策者制定有效的公共卫生政策和资源分配提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
The study aims to understand the prevalence of shingles in China, the burden of disease, and its impact on individuals and the social economy. The specific objectives include: first, to describe and analyze the epidemiological characteristics of shingles in China, including complications, and associated risk factors, in order to better understand the distribution of the disease in different regions and populations. Second, to assess the impact of shingles and its complications on patients' quality of life, including pain, depression, sleep quality, etc., in order to raise public awareness and concern about the impact of the disease. Third, to quantify the burden of shingles on the healthcare system and the social economy, involving medical expenses, productivity loss, family care costs, etc., to provide a basis for policymakers to formulate effective public health policies and resource allocation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
纳入标准是:1)患有带状疱疹;2)年龄40岁及以上;3)在二级医院、三级医院医院疼痛科、皮肤科接受门诊或住院服务;4)具备足够认知能力,能够理解和回答问卷问题;5)知情同意参与研究。 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria: 1) herpes zoster patients; 2) aged 40 and above; 3) inpatient or outpatient at the pain department and dermatology department of secondary and tertiary hospitals; 4) having sufficient cognitive ability to understand and answer questionnaire questions; 5) informed consent to participate in the study. |
||||||||||||||||||||||
|
排除标准: |
排除标准:不能长期居住在本地的居民。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria: residents who cannot live there for a long time. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-02-01 00:00:00至 To 2025-01-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-07-01 00:00:00 至 To 2024-09-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
在合理的要求下,可以与研究负责人联系以获得当前研究中生成或分析的匿名个人数据和数据集。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Anonymized individual-level data and datasets generated or analyzed during the current study are available from the project leader on reasonable request. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
患者人口学特征、共病情况、门诊和住院服务利用与费用,将通过患者就诊医院的电子病例系统患者病案数据中获得;患者免疫缺陷情况、家族史、并发症、疼痛情况、自我治疗和疾病相关的间接成本、生命质量、心理健康和睡眠情况数据将通过电子问卷获得。所有数据将通过STATA15.0进行管理和分析。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Demographic characteristics of patients, comorbidity, utilization and cost of outpatient and inpatient services will be obtained from the patient medical record data of the electronic medical record system of the hospital where the patient visits. Patient data on immune deficiency, family history, complications, pain, self-treatment and disease-related indirect costs, quality of life, and mental health will be obtained via an electronic questionnaire. All data will be managed and analyzed by STATA15.0. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |